Literature DB >> 25439769

Utility of mediastinoscopy in clinical stage I lung cancers at risk for occult mediastinal nodal metastases.

Felix G Fernandez1, Benjamin D Kozower2, Traves D Crabtree3, Seth D Force4, Christine Lau2, Allan Pickens4, Alexander S Krupnick3, Nirmal Veeramachaneni5, G Alexander Patterson3, David R Jones6, Bryan F Meyers3.   

Abstract

OBJECTIVE: The prevalence of mediastinal lymph node metastases is unknown for patients with clinical N0 lung cancer who are thought to be at high risk for occult nodal metastases. Further, the utility of mediastinoscopy in these patients is unknown. We performed a prospective trial to evaluate the utility of routine cervical mediastinoscopy for patients who may be at high risk of occult nodal metastases.
METHODS: From January 1, 2008, July 31, 2013, 90 patients with lung cancer with clinical stage T2N0 or T1N0 with standardized uptake value greater than 10 by positron emission tomography/computed tomography underwent routine cervical mediastinoscopy before lung resection. Biopsy of a minimum of 3 nodal stations at mediastinoscopy and a minimum of 4 nodal stations with lung resection was advised. The prevalence of nodal metastases at mediastinoscopy and lung resection was recorded.
RESULTS: Some 64% of patients with lung cancer were male with a mean age of 67.3 years. A total of 81 patients had clinical T2N0 and 9 patients had T1N0 with standardized uptake value greater than 10. Mean tumor size was 4.3 ± 1.7 cm, and mean standardized uptake value was 13.5 ± 6.8. One patient (1.1%) had occult metastases detected at mediastinoscopy. A total of 86 patients underwent surgical resection; 4 patients (4.6%) were upstaged to pN2, and 18 patients (21%) were upstaged to pN1. Of 90 patients with clinically staged N0 lung cancer by positron emission tomography/computed tomography, 5.6% (5) were upstaged to pN2 and 20% (18) were upstaged to pN1 (total nodal upstaging = 25.6%).
CONCLUSIONS: Mediastinoscopy seems to have limited utility in these patients with T1 and T2 clinically staged N0 by positron emission tomography/computed tomography. Selective use of mediastinoscopy is recommended, along with thorough mediastinal lymph node evaluation in all patients at the time of lung cancer resection. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25439769     DOI: 10.1016/j.jtcvs.2014.08.075

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?

Authors:  Lucyna Kepka; Joanna Socha
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

2.  Cons: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Authors:  Herbert Decaluwé; Christophe Dooms
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis.

Authors:  Chi-Fu Jeffrey Yang; Arvind Kumar; Brian C Gulack; Michael S Mulvihill; Matthew G Hartwig; Xiaofei Wang; Thomas A D'Amico; Mark F Berry
Journal:  J Thorac Cardiovasc Surg       Date:  2015-12-21       Impact factor: 5.209

4.  Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis.

Authors:  Baiqiang Dong; Xuan Zhu; Jianan Jin; Yuanyuan Chen; Hangjie Ying; Yamei Chen; Fangxiao Lu; Wei Shen; Jin Wang; Ming Chen
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

5.  Endobronchial ultrasound elastography strain ratio for mediastinal lymph node diagnosis.

Authors:  Ales Rozman; Mateja Marc Malovrh; Katja Adamic; Tjasa Subic; Viljem Kovac; Matjaz Flezar
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

Review 6.  Cost-effectiveness of endoscopic mediastinal staging.

Authors:  Angelo Carretta
Journal:  Mediastinum       Date:  2020-09-30

7.  Utility of PET-CT in non-small cell lung cancer clinical stage IB-IIA according to AJCC 8th edition staging system: an alternative to invasive mediastinal staging?

Authors:  Agustin Buero; Domingo J Chimondeguy; Rodolfo Auvieux; Gustavo A Lyons; Leonardo G Pankl; Guillermo Puchulo; Silvia Quadrelli
Journal:  Ecancermedicalscience       Date:  2021-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.